Novo Nordisk A/S (NVO)
$53.29
0.69 (1.31%)
NVO Stock Quote Delayed 15 Minutes
Previous Close
$46.40
Market Cap
128.92B
PE Ratio
3.39
EPS
15.73
Volume (Avg. Vol.)
1.19M
Day's Range
53.13 - 53.80
52-Week Range
41.59 - 53.80
Dividend & Yield
0.91 (1.71%)
NVO Stock Predictions, Articles, and Novo Nordisk A/S News
Novo Nordisk Suing Mylan Over Generic Victoza Drug
News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle over a generic version of Victoza.
Quant Score Keeps Novo Nordisk A/S (NVO) Shares a Buy
As one of the 782 companies in the GICS Health Care sector Novo Nordisk A/S (NYSE:NVO) is a constituent of the 134 company Pharmaceuticals GICS industry group within this sector. NVO has a market value of $102.0 billion which is in the top 10% of its industry group. Portfolio Grader's current ranking for NVO puts it 14 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 110 among the 782 companies in the sector, and number 634 in the nearly 5,000 company Portfolio Grader universe.
Novo Nordisk A/S (NVO) a Strong Buy on Top-End Quant Score
Novo Nordisk A/S (NYSE:NVO) is one of the 781 companies in the GICS Health Care sector, and a component of the 134 company Pharmaceuticals GICS industry group within this sector. The market value of NVO is $102.5 billion which places it in the top 10% of its industry group. The stock's current Portfolio Grader score places it 4 among the 134 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 46 among the 781 companies in the sector, and number 257 in the nearly 5,000 company Portfolio Grader universe.
High-Level Quant Score Keeps Novo Nordisk A/S (NVO) a Strong Buy
Novo Nordisk A/S (NYSE:NVO) is one of the 781 companies in the GICS Health Care sector, and a component of the 133 company Pharmaceuticals GICS industry group within this sector. NVO's market value is $99.9 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader score places it 4 among the 133 companies in this industry group, putting it in the top decile; among the sector leaders with a ranking of 48 among the 781 companies in the sector, and number 254 in the nearly 5,000 company Portfolio Grader universe.
Novo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings Momentum
Novo Nordisk A/S (NYSE:NVO) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top decile of sector group, Health Care, with a market value of $98.0 billion. From an investment attractiveness viewpoint, NVO is ranked in the top decile of the sector with a ranking of 28 among the 782 companies in the sector; the stock's current Portfolio Grader score places it 2 among the 132 companies in this industry group, putting it in the top decile and number 224 in the 5000 company Portfolio Grader company universe.
High-End Earnings Visibility Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong Buy
With a $98.0 billion market value, Novo Nordisk A/S (NYSE:NVO) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader score places it 2 among the 133 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 29 among the 785 companies in the sector, and number 206 in the nearly 5,000 company Portfolio Grader universe.
Exceptional Quant Score Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong Buy
With a $97.2 billion market value, Novo Nordisk A/S (NYSE:NVO) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader score places it 3 among the 133 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 33 among the 783 companies in the sector, and number 218 in the nearly 5,000 company Portfolio Grader universe.
Novo Nordisk A/S’s (NVO) Solid Quant Score Makes it a Buy
The current recommendation of Buy for Novo Nordisk A/S (NYSE:NVO) is derived using Louis Navellier's investing methods and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month.
Earnings Visibility Makes Novo Nordisk A/S (NVO) a Buy
Novo Nordisk A/S (NYSE:NVO) is a $93.3 billion in market value constituent of the Pharmaceuticals GICS industry group where Portfolio Grader's current ranking for NVO puts it 29 among the 135 companies in this industry group, giving it a well above-average position. NVO is ranked in the top half of the sector with a ranking of 203 among the 783 companies in the sector and number 1,464 in the 5000 company Portfolio Grader company universe.
Novo Nordisk A/S’s (NVO) Stock Has Hold Recommendation Remain in Place
Portfolio Grader currently ranks Novo Nordisk A/S (NYSE:NVO) a Hold. The approach to investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for the last month.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Soars on New CEO News
Teva Pharmaceutical (TEVA) stock was flying high today following news of a new CEO that will be joining the company soon.
5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must
Global Blood Therapeutics Inc (GBT) Stock Soars on Takeover Talk
Global Blood Therapeutics (GBT) stock is rising as the company is being targeted for a takeover by another pharma corporation. Here's what's happenig
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
